Petrovax Pharm to launch exports of medicinal products to South Africa

The Russian biopharmaceutical company Petrovax Pharm has obtained marketing authorization for its original medicinal product Polyoxidonium ® in the Republic of Botswana. This is the company’s first step toward entering the South African market. Going forward, Petrovax Pharm plans to expand its presence in the region, including the market of the Republic of South Africa. The registration of Polyoxidonium in Botswana was carried out in accordance with the requirements of the national regulator and included a comprehensive assessment of the registration dossier and product samples. One of the key factors behind the successful completion of the procedure was the product’s existing registration in Slovakia, confirming its compliance with European requirements for quality, safety, and efficacy. The product has been in use in that country for more than 15 years. A further advantage was the EU Good Manufacturing Practice (GMP) certificate held by the Petrovax Pharm manufacturing site. In bringing the product to the Botswana market, the company took into account the specific features of the region’s epidemiological situation. Polyoxidonium ® has an extensive body of clinical evidence for use in diseases relevant to Southern African countries, which makes the product valuable for the region’s healthcare system. "Entering the Botswana market is a significant milestone in the development of the company’s export business. We view this country as an entry point to the Southern Africa region. The experience gained in registration and in engaging with the local regulator and partners will serve as a foundation for further export expansion in this region," said Ilya Sokolov, Head of Export at Petrovax Pharm.

The release as fetched from its publisher. petrovax.com ↗